CorMedix (CRMD) Ignites Investor Buzz As DefenCath Revenue Skyrockets
Second-quarter profits and blockbuster expansion deal fuel bullish sentiment in biotech circles
CorMedix (NASDAQ: CRMD) is on fire today, captivating investors with its explosive DefenCath revenue growth and a planned acquisition that could broaden its market reach. This biopharmaceutical company, listed on the Nasdaq Global Market and operating in the Medical-Biomed/Biotech sector, is gaining significant attention as its Q2 results and strategic moves hit the wire.
The company just posted a staggering $39.7 million in Q2 2025 net revenue from sales of DefenCath, up from just $0.8 million a year ago, signaling an almost 50-fold surge year-over-year. On the bottom line, CorMedix delivered net income of $19.8 million (≈ $0.29 per share), flipping from a loss of $14.2 million in Q2 2024. For the first half of 2025, revenue totaled $78.8 million, and net income reached $40.5 million, versus a loss of $28.6 million in the prior year.
The financials shine even brighter when you consider that CorMedix achieved a 95% gross margin, reinforcing how economically efficient DefenCath is. Moreover, liquidity remains robust: as of June 30, 2025, the company held $190.7 million in cash and short-term investments, sufficient to fund operations for at least the next year.
On top of the numbers, CorMedix is executing hard on strategic expansion. A major Large Dialysis Organization (LDO) has ramped up DefenCath usage, leading CorMedix to boost its Q2 sales guidance to $35–40 million, up from $31 million. This news sent CRMD shares soaring to a four-year high, up 21.7%, showcasing the market’s bullish confidence.
The company is also moving to acquire Melinta Therapeutics in a $300 million cash-and-stock deal, expected to close around September 1, 2025, diversifying its pipeline beyond DefenCath. To help fund that, CorMedix plans to issue $150 million in senior convertible notes due 2030.
Adding to the momentum, CorMedix has received a jump in its Relative Strength Rating to 92, signaling strong market leadership among Biotech peers.
All this activity unfolds as CRMD trades at around $12.93 today (up from $12.61), within a 52-week range of roughly $4.68 to $17.43.
In short, CorMedix is staging a powerful commercial and strategic breakout, with DefenCath delivering real revenue inflection, a deepening institutional rollout, and a savvy acquisition strategy. Investors are buzzing—and with ticker CRMD under the spotlight in the Biotech sector on Nasdaq, all eyes remain fixed on the next catalysts.